Literature DB >> 30260737

Systems Pharmacology: Defining the Interactions of Drug Combinations.

J G Coen van Hasselt1,2, Ravi Iyengar1.   

Abstract

The majority of diseases are associated with alterations in multiple molecular pathways and complex interactions at the cellular and organ levels. Single-target monotherapies therefore have intrinsic limitations with respect to their maximum therapeutic benefits. The potential of combination drug therapies has received interest for the treatment of many diseases and is well established in some areas, such as oncology. Combination drug treatments may allow us to identify synergistic drug effects, reduce adverse drug reactions, and address variability in disease characteristics between patients. Identification of combination therapies remains challenging. We discuss current state-of-the-art systems pharmacology approaches to enable rational identification of combination therapies. These approaches, which include characterization of mechanisms of disease and drug action at a systems level, can enable understanding of drug interactions at the molecular, cellular, physiological, and organismal levels. Such multiscale understanding can enable precision medicine by promoting the rational development of combination therapy at the level of individual patients for many diseases.

Entities:  

Keywords:  QSP; combination therapy; modeling; pharmacodynamics; quantitative systems pharmacology; systems biology; systems pharmacology

Mesh:

Substances:

Year:  2018        PMID: 30260737     DOI: 10.1146/annurev-pharmtox-010818-021511

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  16 in total

1.  Hybrid fusion protein as a dual protease inhibitor for the healing of chronic wounds.

Authors:  Graham Strauss; Piyush Koria
Journal:  Biotechnol Prog       Date:  2021-09-16

Review 2.  Phenotypic drug discovery: recent successes, lessons learned and new directions.

Authors:  Fabien Vincent; Arsenio Nueda; Jonathan Lee; Monica Schenone; Marco Prunotto; Mark Mercola
Journal:  Nat Rev Drug Discov       Date:  2022-05-30       Impact factor: 112.288

Review 3.  Machine learning approaches for drug combination therapies.

Authors:  Betül Güvenç Paltun; Samuel Kaski; Hiroshi Mamitsuka
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 11.622

4.  Transit-Amplifying Cells Coordinate Changes in Intestinal Epithelial Cell-Type Composition.

Authors:  Laura E Sanman; Ina W Chen; Jake M Bieber; Veronica Steri; Coralie Trentesaux; Byron Hann; Ophir D Klein; Lani F Wu; Steven J Altschuler
Journal:  Dev Cell       Date:  2021-01-22       Impact factor: 12.270

5.  Connectivity Mapping Identifies BI-2536 as a Potential Drug to Treat Diabetic Kidney Disease.

Authors:  Lu Zhang; Zichen Wang; Ruijie Liu; Zhengzhe Li; Jennifer Lin; Megan L Wojciechowicz; Jiyi Huang; Kyung Lee; Avi Ma'ayan; John Cijiang He
Journal:  Diabetes       Date:  2020-10-16       Impact factor: 9.461

6.  Identification of disease treatment mechanisms through the multiscale interactome.

Authors:  Camilo Ruiz; Marinka Zitnik; Jure Leskovec
Journal:  Nat Commun       Date:  2021-03-19       Impact factor: 14.919

7.  A systems pharmacology approach based on oncogenic signalling pathways to determine the mechanisms of action of natural products in breast cancer from transcriptome data.

Authors:  Regan Odongo; Asuman Demiroglu-Zergeroglu; Tunahan Çakır
Journal:  BMC Complement Med Ther       Date:  2021-06-30

Review 8.  Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors.

Authors:  Maddalena Centanni; Dirk Jan A R Moes; Iñaki F Trocóniz; Joseph Ciccolini; J G Coen van Hasselt
Journal:  Clin Pharmacokinet       Date:  2019-07       Impact factor: 6.447

Review 9.  Drug-drug cocrystals: Opportunities and challenges.

Authors:  Xiaojuan Wang; Shuzhang Du; Rui Zhang; Xuedong Jia; Ting Yang; Xiaojian Zhang
Journal:  Asian J Pharm Sci       Date:  2020-07-09       Impact factor: 6.598

10.  An Integrated Analysis of Network Pharmacology, Molecular Docking, and Experiment Validation to Explore the New Candidate Active Component and Mechanism of Cuscutae Semen-Mori Fructus Coupled-Herbs in Treating Oligoasthenozoospermia.

Authors:  Xue Bai; Yibo Tang; Qiang Li; Dan Liu; Guimin Liu; Xiaolei Fan; Zhejun Liu; Shujun Yu; Tian Tang; Shuyan Wang; Lingru Li; Kailin Zhou; Yanfei Zheng; Zhenquan Liu
Journal:  Drug Des Devel Ther       Date:  2021-05-17       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.